An Articular Defects or a chondral injury may occur as a result of a twist or pivot on a bent knee, direct blow to the knee, or wear and tear as an individual gets older. In some of the cases, Articular Defects is an injury to a ligament such as the anterior crutiate ligament (ACL). In Articular Defects, small pieces of cartilage break down and float around in the joints or in close proximity which causes locking, catching and swelling. For most of the patients, there is no clear history reported of a single injury, rather, the injury is resultant of a series of minor injuries that have occurred over a duration. When the cartilage gets damaged, the condition is called chondromalacia, which is also called osteoarthritis. Articular defects can occur in children, adults, and the geriatrics. The treatment of articular defects depends on the location and size of the defect. In general, the defects that are on the end of the femur, are the easiest to treat and have the best outcomes. Articular defects on the kneecap and tibia are harder to treat and the results aren’t reliable. For the patients who have very deep articular defects, which extend all the way down to the bone, the treatment of such articular defects depend upon the location and the overall diameter of the defect. For smaller articular defects, a technique known as microfracture, which relies on the patients stem cells, can be used.
Articular Defects Treatment Market: Drivers and Restraints
The growing prevalence and recurrence of osteoarthritis, obesity, metabolic syndrome, and articular defects is expected to be the major factor driving the growth of the articular defects treatment market over the forecast period. As per a survey published by NCBI in 2015, obesity, and dietary factors, joint loading and injury, and joint shape and alignment are some major factors which contribute to the increasing prevalence of osteoarthritis, which in turn is one the major factors resulting in articular defects. Launch and addition of new kinds of methods and devices are some of the other factors contributing to the growth of the global Articular Defects Treatment Market. For instance, the European Medicines Agency (EMA) has recommended granting and marketing authorization in the European Union for a new Advanced Therapy Medicinal Product(ATMP), Spherox, to treat adult patients who have symptomatic articular defects which are in the femoral and patellofemoral.
You can Get Free Sample Report Here @ https://www.factmr.com/connectus/sample?flag=S&rep_id=1697Source: Click here